


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (currently amended) A compound of the general formula (I)



wherein


R¹ is ~~selected from~~ hydrogen; a branched or straight C₁-C₆ alkyl; C₁-C₆ alkenyl; C₃-C₈ cycloalkyl; C₄-C₈(alkyl-cycloalkyl); wherein alkyl is C₁-C₂ alkyl and cycloalkyl is C₃-C₆ cycloalkyl; C₆-C₁₀ aryl; or heteroaryl having from 5 to 10 atoms selected from ~~any of~~ C, S, N and/or O; wherein ~~the said~~ aryl and/or heteroaryl may optionally and independently be substituted by 1 or 2 substituents ~~independently selected from any of~~ hydrogen, CH₃, (CH₂)_pCF₃, halogen, CONR⁵R⁴, COOR⁵, COR⁵, (CH₂)_pNR⁵R⁴, (CH₂)_pCH₃, (CH₂)_pSOR⁵R⁴, (CH₂)_pSO₂R⁵, (CH₂)_pSO₂NR⁵R⁴ and (CH₂)_pOR⁵, wherein p is 0, 1 or 2; (C₁-C₂ alkyl)-(C₆-C₁₀ aryl); or (C₁-C₂ alkyl)heteroaryl, ~~the wherein said heteroaryl moieties having has~~ from 5 to 10 atoms selected from ~~any of~~ C, S, N and/or O, and wherein ~~the said~~ aryl and/or heteroaryl may optionally and independently be substituted by 1 or 2 substituents ~~independently selected from any of~~ hydrogen, CH₃, ~~(CH₂)_qCF₃, (CH₂)_qCF₃~~, halogen, -CONR⁵R⁴, -COOR⁵, -COR⁵, -(CH₂)_qNR⁵R⁴, -(CH₂)_qCH₃, (CH₂)_qSOR⁵R⁴, -(CH₂)_qSO₂R⁵, -(CH₂)_qSO₂NR⁵R⁴, and ~~(CH₂)_pOR⁵, (CH₂)_qOR⁵~~, wherein q is 0, 1 or 2; and



R¹⁹, R²⁰, R²¹, R²², R²³, and R²⁴ is each and independently selected from hydrogen, C₁-C₆ alkyl, and or C₁-C₆ alkenyl;

R^2 and R^3 is each and independently selected from hydrogen and C_1 - C_6 alkyl;

A is ~~selected from~~



wherein the phenyl ring of each A is substituent may be optionally and independently substituted by 1 or 2 substituents Z^1 and Z^2 each and independently selected from hydrogen, CH_3 , $-(CH_2)_rCF_3$, $-(CH_2)_rCF_3$, halogen, $-CONR^6R^7$, $-CO_2R^6$, $-COR^6$, $-(CH_2)_rNR^6R^7$, $-(CH_2)_rCH_3$, $-(CH_2)_rSOR^6$, $-(CH_2)_rSO_2R^6$ and $-(CH_2)_rSO_2NR^6R^7$ wherein r is 0, 1, or 2;


Q is C_5 - C_6 hydroaryl; ~~or~~ heterohydroaromatic having 5 or 6 atoms selected from ~~anyone of~~ C, S, N and/or O; C_5 - C_6 cycloalkyl; ~~or~~ heterocycloalkyl having 5 or 6 atoms selected from ~~any one of~~ C, N, O and/or S; and wherein each Q may is optionally be substituted by a substituent Z^1 and Z^2 as defined above;

B is ~~selected from phenyl, or naphthyl, wherein the phenyl and naphthyl is optionally and independently substituted by 1 or 2 substituents independently selected from hydrogen, CH_3 , $-(CH_2)_tCF_3$, halogen, $-(CH_2)_tCONR^5R^4$, $-(CH_2)_tNR^5R^4$, $-(CH_2)_tCOR^5$, $-(CH_2)_tCOOR^5$, $-OR^5$, $-(CH_2)_tSOR^5$, $-(CH_2)_tSO_2R^5$, and $-(CH_2)_tSO_2NR^5R^4$, and wherein t is 0, 1, 2 or 3; and~~

R^4 , R^5 , R^6 , and R^7 is each and independently selected from hydrogen; a branched or straight C_1 - C_6 alkyl; C_1 - C_6 alkenyl; C_3 - C_8 cycloalkyl; and C_4 - C_8 (alkyl-cycloalkyl); wherein alkyl is C_1 - C_2 alkyl and cycloalkyl is C_3 - C_6 cycloalkyl;

as well as pharmaceutically acceptable salts of the compounds of the formula (I), and isomers, hydrates, isoforms and prodrugs thereof.

2. (currently amended) A compound of the formula (I) according to claim 1, wherein



A is ~~selected from~~ wherein the phenyl ring of each A is ~~substituent may be~~ optionally and independently substituted at any position of the phenyl ring by 1 or 2 substituents Z^1 and Z^2 which ~~are~~ is each and independently selected from hydrogen, CH_3 , $-(\text{CH}_2)_q\text{CF}_3$, $-(\text{CH}_2)_r\text{CF}_3$, halogen, $-\text{CONR}^6\text{R}^7$, $-\text{COOR}^6$, $-\text{COR}^6$, $-(\text{CH}_2)_r\text{NR}^6\text{R}^7$, $-(\text{CH}_2)_r\text{CH}_3$, $-(\text{CH}_2)_r\text{SOR}^6$, $-(\text{CH}_2)_r\text{SO}_2\text{R}^6$ and $-(\text{CH}_2)_r\text{SO}_2\text{NR}^6\text{R}^7$, wherein r is 0, 1, or 2;

Q is ~~selected from~~ morpholine, piperidine, or ~~and~~ pyrrolidine;

R^1 is ~~selected from~~ hydrogen; a branched or straight C_1 - C_4 alkyl; C_3 - C_5 cycloalkyl; C_4 - C_8 (alkyl-cycloalkyl); wherein alkyl is C_1 - C_2 alkyl and cycloalkyl is C_3 - C_6 cycloalkyl; and C_6 - C_{10} aryl; ~~and or~~ heteroaryl having from 5 to 6 atoms selected from ~~any of~~ C, S, N and or O; ~~and wherein~~ the aryl and/or heteroaryl ~~may is~~ optionally and independently be substituted by 1 or 2 substituents independently selected from ~~any of~~ hydrogen, CH_3 , $-(\text{CH}_2)_p\text{CF}_3$, halogen, $-\text{CONR}^5\text{R}^4$, $-\text{COOR}^5$, $-\text{COR}^5$, $-(\text{CH}_2)_p\text{NR}^5\text{R}^4$, $-(\text{CH}_2)_p\text{CH}_3$, $-(\text{CH}_2)_p\text{SOR}^5\text{R}^4$, $-(\text{CH}_2)_p\text{SO}_2\text{R}^5$, and $-(\text{CH}_2)_p\text{SO}_2\text{NR}^5\text{R}^4$, wherein p is 0, 1 or 2;


B is ~~selected from~~ phenyl; ~~and or~~ naphthyl, wherein the phenyl and naphthyl is each optionally and independently substituted by 1 or 2 substituents ~~independently~~ selected from hydrogen, CH_3 , CF_3 , halogen, $-(\text{CH}_2)_q\text{CONR}^5\text{R}^4$, $-(\text{CH}_2)_q\text{NR}^5\text{R}^4$, $-(\text{CH}_2)_q\text{COR}^5$, $-(\text{CH}_2)_q\text{CO}_2\text{R}^5$, and $-\text{OR}^5$; wherein q is 0 or 1; ~~and wherein~~

R^4 , R^5 , R^6 , and R^7 ; is each and independently selected from hydrogen, a branched or straight C_1 - C_6 alkyl, C_1 - C_6 alkenyl, C_3 - C_8 cycloalkyl, and C_4 - C_8 (alkyl-cycloalkyl) wherein alkyl is C_1 - C_2 alkyl and cycloalkyl is C_3 - C_6 cycloalkyl; and

R^2 and R^3 is each and independently selected from hydrogen ~~or~~ and methyl.

3. (canceled)

4. (currently amended) A compound of the formula (I) according to claim 1, which compound is



, wherein R is morpholine, piperidine or pyrrolidine;

5. (canceled).

6. (currently amended) A compound according to claim 1 ~~any of the preceding claims~~, in form of its hydrochloride, sulfate, tartrate or citrate salts.

7-14. (canceled)

15. (currently amended) A compound according to claim 1, wherein said compound ~~further characterised in that it is isotopically labelled~~.

16. (canceled).

17. (original) An isotopically labelled compound of the formula (I) of claim 1.

18. (canceled).

19. (original) A pharmaceutical composition comprising a compound of the formula (I) according to claim 1 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.

20-26. (canceled)

27. (new) A compound according to claim 4, in form of its hydrochloride, sulfate, tartrate or citrate salts.

28. (new) A pharmaceutical composition comprising a compound of the formula (I) according to claim 4 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.

29. (new) A compound according to claim 2, wherein B is a phenyl substituted by 1 substituent selected from halogen.

30. (new) A compound according to claim 29, wherein the halogen is fluorine.

31. (new) A compound according to claim 30, wherein said phenyl is substituted at the meta position by said fluorine.

31. (new) A compound according to claim 29, wherein Z^1 , Z^2 , and R^1 is each and independently H; and R^2 and R^3 is each and independently selected from H and CH_3 .

32. (new) A compound according to claim 31, wherein Z^1 , Z^2 , R^1 , R^2 , and R^3 is each and independently H.

33. (new) A compound according to claim 29, wherein Z^1 , Z^2 , R^1 , R^2 , and R^3 is each and independently H.

34. (new) A compound according to claim 4, wherein said compound is isotopically labeled.

35. (new) A compound according to claim 1, wherein the compound is selected from:

- 4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-morpholin-4-yl-methanone;
- 4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-piperidin-1-yl-methanone; and
- 4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-pyrrolidin-1-yl-methanone.